1-Bromo-4-fluorobenzene → 8-(1-(4-fluorophenyl)pyrrolidin-2-yl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide

HRID 463

反応式

HRID 463 の反応式
CN(C)C(=O)c1cc(C2CCCN2)c2oc(N3CCOCC3)cc(=O)c2c1.Fc1ccc(Br)cc1>C1COCCO1.CC(=O)O.CC(=O)O.O=C([O-])[O-].[Cs+].[Cs+].[Pd].c1ccc(-c2ccccc2P(C2CCCCC2)C2CCCCC2)cc1>CN(C)C(=O)c1cc(C2CCCN2c2ccc(F)cc2)c2oc(N3CCOCC3)cc(=O)c2c1

参加物

7

反応条件

温度
100 °C

実験手順

diacetoxypalladium (7.56 mg, 0.03 mmol) was added to a stirred mixture of N,N-dimethyl-2-morpholino-4-oxo-8-(pyrrolidin-2-yl)-4H-chromene-6-carboxamide (250 mg, 0.67 mmol), biphenyl-2-yldicyclohexylphosphine (23.59 mg, 0.07 mmol), 1-bromo-4-fluorobenzene (0.092 ml, 0.84 mmol) and cesium carbonate (329 mg, 1.01 mmol) dissolved in 1,4-dioxane (5 ml). The resulting suspension was degased with argon and then stirred at 100 °C for 15 hours. The reaction mixture was allowed to cool to room temperature and concentrated. The crude product was dissolved in DMA. The reaction mixture was purified by preparative HPLC using a Waters X-Bridge reverse-phase column (C-18, 5 microns silica, 30 mm diameter, 150 mm length, flow rate of 60 ml / minute) and decreasingly polar mixtures of water (containing 0.2% ammonium carbonate) and acetonitrile as eluent. The fractions containing the desired compound were evaporated to dryness to afford 8-(1-(4-fluorophenyl)pyrrolidin-2-yl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (155 mg, 49.5 %) as a gum 200mg (155mg from EN05368-13 and 45mg from EN04870-97) was sent to the collection and purified by chiral separation.

出典と根拠

ORDレコード
ord-3af268f385e348b58c53e9a70feadd8e
出典データセット
750 AstraZeneca ELN dataset
元リンク
出典を表示

関連ノート

読み込み中…